Item 4. Controls and Procedures
Item
4. Controls and Procedures
Evaluation
of Disclosure Controls and Procedures
As
required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, under the direction
of the Chief Executive Officer and the Chief Financial Officer, we have evaluated our disclosure controls and procedures as of the end
of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial
Officer have concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report.
Our management has concluded that the financial statements included elsewhere in this Quarterly Report present fairly, in all material
respects, our financial position, results of operations and cash flows in conformity with generally accepted accounting principles.
Changes
in Internal Control over Financial Reporting
There
has not been any change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) and 15d-15(f) under
the Exchange Act) during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably
likely to materially affect our internal control over financial reporting.
34
NeuroOne Medical Technologies Corporation
Form 10-Q
PART
II – OTHER INFORMATION
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.